Aniracetam vs CMS121

N/A

N/A

Aniracetam is marketed in Greece as Referan (750 mg tablets and 1500 mg sachets) and in Italy as Ampamet/Draganon, representing real-world prescription doses in those jurisdictions, but no FDA-reviewed human dosing regimen exists. The compound exhibits very rapid and essentially complete GI absorption but undergoes extensive first-pass hepatic hydrolysis, yielding an absolute systemic bioavailability of the parent compound of only ~0.2% with a short half-life (~0.5 h); roughly 70% of the dose is converted to the active metabolite N-anisoyl-GABA. Independent laboratory testing of US nootropic supplements found aniracetam at 0.5–502 mg per serving versus a 200–750 mg pharmaceutical range, with 75% of products showing label-content mismatches. As a non-peptide small molecule, aniracetam does not require refrigeration.

The Phase 1 trial in healthy volunteers explored single doses up to 1800 mg and repeat doses up to 900 mg/day (young adults) or 600 mg/day (elderly) for 7 days as safety and pharmacokinetics exploration doses, not established therapeutic doses. Pharmacokinetics showed significant age effects (higher exposure in elderly) and food effects (~50% increase in fed state). No validated safe or effective chronic dosing regimen exists for any medical indication. CMS121 is a non-peptide small molecule; some vendors incorrectly label it as a "peptide."